<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Tuberous sclerosis complex: Genetics and pathogenesis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Tuberous sclerosis complex: Genetics and pathogenesis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Tuberous sclerosis complex: Genetics and pathogenesis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stephanie Randle, MD, MS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Helen V Firth, DM, FRCP, FMedSci
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alberto S Pappo, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marc C Patterson, MD, FRACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John F Dashe, MD, PhD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 06, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H379368247">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tuberous sclerosis complex (TSC) is an inherited neurocutaneous disorder that is characterized by pleomorphic features involving many organ systems, including multiple benign hamartomas of the brain, eyes, heart, lung, liver, kidney, and skin.
        </p>
        <p>
         The genetics and pathogenesis of TSC will be reviewed here. Other aspects of TSC are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/6175.html" rel="external">
          "Tuberous sclerosis complex: Clinical features"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16902.html" rel="external">
          "Tuberous sclerosis complex: Management and prognosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1684.html" rel="external">
          "Renal manifestations of tuberous sclerosis complex"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4329.html" rel="external">
          "Tuberous sclerosis complex associated lymphangioleiomyomatosis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1494449695">
         <span class="h1">
          GENETICS
         </span>
        </p>
        <p class="headingAnchor" id="H644627057">
         <span class="h2">
          <i>
           TSC1
          </i>
          and
          <i>
           TSC2
          </i>
          pathogenic variants
         </span>
         <span class="headingEndMark">
          —
         </span>
         TSC is an autosomal dominant genetic disorder caused by heterozygous pathogenic variants in either the TSC complex subunit 1 (
         <em>
          TSC1
         </em>
         ) or the TSC complex subunit 2 (
         <em>
          TSC2
         </em>
         ) tumor suppressor genes. These variants cause overactivation of the mechanistic target of rapamycin (mTOR) pathway and tumor formation in multiple organs [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="local">
          'Mechanism of tumor formation'
         </a>
         below.)
        </p>
        <p>
         Pathogenic variants in
         <em>
          TSC1
         </em>
         and
         <em>
          TSC2
         </em>
         were first identified in genetic linkage analysis of families with TSC [
         <a href="#rid2">
          2,3
         </a>
         ]. Both genes were subsequently cloned and the spectrum of pathogenic variants in TSC patients described [
         <a href="#rid4">
          4-6
         </a>
         ]. Most
         <em>
          TSC1
         </em>
         and
         <em>
          TSC2
         </em>
         pathogenic variants result in loss of functional protein products [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2707350958">
         <span class="h3">
          The
          <i>
           TSC1
          </i>
          gene
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pathogenic variants in
         <em>
          TSC1
         </em>
         account for approximately one-third of TSC cases with identified pathogenic variants [
         <a href="#rid7">
          7-9
         </a>
         ]. The
         <em>
          TSC1
         </em>
         gene, which maps to chromosome 9q34, spans 50 kb of genomic deoxyribonucleic acid (DNA) and contains 23 exons [
         <a href="#rid4">
          4
         </a>
         ].
         <em>
          TSC1
         </em>
         encodes a protein termed hamartin, which is widely expressed in normal tissues [
         <a href="#rid10">
          10
         </a>
         ]. Hamartin forms a complex with the tuberin protein that is encoded by the
         <em>
          TSC2
         </em>
         gene [
         <a href="#rid11">
          11,12
         </a>
         ]. The functions of these proteins are described below. (See
         <a class="local">
          'Mechanism of tumor formation'
         </a>
         below.)
        </p>
        <p>
         Several different types of
         <em>
          TSC1
         </em>
         pathogenic variants have been identified, most of which result in a truncated protein with loss of function [
         <a href="#rid13">
          13
         </a>
         ]. These include small deletions and insertions (58 percent), nonsense variants (23 percent), splicing variants (11 percent), missense variants (6 percent), and large deletions and rearrangements (3 percent) [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3222695811">
         <span class="h3">
          The
          <i>
           TSC2
          </i>
          gene
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pathogenic variants in
         <em>
          TSC2
         </em>
         account for approximately two-thirds of TSC cases with identified pathogenic variant [
         <a href="#rid7">
          7-9
         </a>
         ]. The
         <em>
          TSC2
         </em>
         gene, which maps to chromosome 16p13.3, spans 45 kB of genomic DNA and contains 42 exons [
         <a href="#rid5">
          5
         </a>
         ]. The gene is ubiquitously expressed in all normal adult tissues [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         <em>
          TSC2
         </em>
         encodes the tuberin protein. Tuberin forms a complex with the hamartin protein, the product of the
         <em>
          TSC1
         </em>
         gene [
         <a href="#rid11">
          11,12
         </a>
         ].
        </p>
        <p>
         <em>
          TSC2
         </em>
         functions in normal brain development [
         <a href="#rid15">
          15
         </a>
         ] and in withdrawal of the normal cardiomyocyte from the cell cycle during terminal differentiation [
         <a href="#rid16">
          16
         </a>
         ]. This latter finding is potentially relevant in view of the benign cardiac tumors (rhabdomyomas) that are seen in TSC. (See
         <a class="medical medical_review" href="/z/d/html/6175.html" rel="external">
          "Tuberous sclerosis complex: Clinical features", section on 'Cardiovascular manifestations'
         </a>
         .)
        </p>
        <p>
         As with
         <em>
          TSC1
         </em>
         , the majority of pathogenic variants identified in
         <em>
          TSC2
         </em>
         are loss-of-function variants [
         <a href="#rid17">
          17-19
         </a>
         ]. These include small deletions and insertions (38 percent); missense (26 percent), nonsense (15 percent), and splice variants (17 percent); and large deletions and rearrangements (5 percent) [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Certain
         <em>
          TSC2
         </em>
         missense variants inhibit tuberin phosphorylation, preventing the formation of the tuberin-hamartin complex [
         <a href="#rid20">
          20
         </a>
         ]. Other pathogenic variants in both
         <em>
          TSC1
         </em>
         and
         <em>
          TSC2
         </em>
         also disrupt the interaction between these two proteins [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3942775132">
         <span class="h3">
          Molecular genetic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         A disease-causing pathogenic variant can be identified by conventional molecular genetic testing (eg, gene-targeted sequence analysis and deletion/duplication analysis) in 85 to 90 percent of patients who meet the diagnostic criteria for TSC [
         <a href="#rid7">
          7,8,22,23
         </a>
         ]. With next-generation sequencing, targeted
         <em>
          TSC1
         </em>
         /
         <em>
          TSC2
         </em>
         gene panels can identify a causative pathogenic variant in &gt;90 percent of patients with TSC but still not in all [
         <a href="#rid8">
          8,9,24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/143210.html" rel="external">
          "Tuberous sclerosis complex: Evaluation and diagnosis", section on 'Genetic testing'
         </a>
         .)
        </p>
        <p>
         Mosaicism and noncoding pathogenic variants probably account for most of those with no pathogenic variant identified. In one report of 53 individuals with TSC who had no pathogenic variant identified after conventional genetic assessment, next-generation sequencing of tissue samples, including blood, saliva, and skin tumor biopsies, identified pathogenic variants in 45 (85 percent) [
         <a href="#rid8">
          8
         </a>
         ]. Among these 45 subjects, mosaicism was present in 28 individuals, and intronic pathogenic variants were found in 18. These data suggest that next-generation sequencing with full gene analysis and testing of TSC-related tumors can increase the detection rate of pathogenic variants.
        </p>
        <p class="headingAnchor" id="H1907955902">
         <span class="h2">
          De novo versus familial TSC
         </span>
         <span class="headingEndMark">
          —
         </span>
         De novo germline pathogenic variants account for approximately 80 percent of TSC cases, with
         <em>
          TSC2
         </em>
         pathogenic variants being approximately two times as common as
         <em>
          TSC1
         </em>
         pathogenic variants among de novo cases. The prevalence of
         <em>
          TSC1
         </em>
         and
         <em>
          TSC2
         </em>
         pathogenic variants is approximately equal among familial TSC cases [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         There are several different explanations for the apparently nonfamilial cases.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Most often, such cases result from a de novo pathogenic variant in the egg or sperm prior to fertilization.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Parental somatic mosaicism, where a subset of the parent's somatic and germ cells carry the pathogenic variant, or gonadal mosaicism, in which mosaicism is confined to the parental germline [
         <a href="#rid25">
          25-27
         </a>
         ]. In germline mosaicism, there may be more than one egg or sperm that contains the pathogenic variant, which can result in more than one sibling affected with the disease (ie, there is an appreciable recurrence risk).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a child with no affected parents or siblings, TSC may be the result of somatic mosaicism where the pathogenic variant occurred de novo after fertilization during one of the early cell divisions [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Once a de novo germline pathogenic variant occurs in an individual, their offspring will have a 50 percent chance of inheriting TSC, which then follows an autosomal dominant pattern of inheritance in later generations. (See
         <a class="medical medical_review" href="/z/d/html/143210.html" rel="external">
          "Tuberous sclerosis complex: Evaluation and diagnosis", section on 'Genetic testing'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3428912896">
         <span class="h2">
          Penetrance and expressivity
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Penetrance
         </strong>
         – The penetrance of TSC is complete, meaning that all individuals with a
         <em>
          TSC1
         </em>
         or
         <em>
          TSC2
         </em>
         pathogenic variant will manifest some features of TSC. However, the phenotype can be subtle in some cases [
         <a href="#rid7">
          7,9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Highly variable expressivity
         </strong>
         – TSC is highly variable in its expression, that is, in the range of phenotypic changes such as age of onset, severity of disease, and different signs and symptoms that result from a specific genotype. (See
         <a class="medical medical_review" href="/z/d/html/2897.html" rel="external">
          "Inheritance patterns of monogenic disorders (Mendelian and non-Mendelian)", section on 'Penetrance and expressivity'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Thus, the severity of disease in TSC can vary substantially among affected individuals within the same family, and particularly from one family to another [
         <a href="#rid28">
          28,29
         </a>
         ]. The variability is due to multiple causes. These include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Somatic mosaicism (individuals who have low-level mosaicism for a TSC-associated pathogenic variant may be very mildly affected) [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Differences between
         <em>
          TSC1
         </em>
         and
         <em>
          TSC2
         </em>
         pathogenic variants. (See
         <a class="local">
          'Genotype-phenotype correlations'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The requirement for a secondary somatic pathogenic variant in the wildtype copy of the gene for the development of many pathologic features of TSC [
         <a href="#rid30">
          30,31
         </a>
         ]. The latter feature is consistent with the two-hit hypothesis of Knudson, in which one pathogenic variant is inherited and the second is acquired in somatic tissues [
         <a href="#rid32">
          32
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6275.html" rel="external">
          "Retinoblastoma: Clinical presentation, evaluation, and diagnosis", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H627669847">
         <span class="h2">
          Genotype-phenotype correlations
         </span>
        </p>
        <p class="headingAnchor" id="H596288729">
         <span class="h3">
          <i>
           TSC2
          </i>
          variants
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           TSC2
          </em>
         </strong>
         <strong>
          variants have a tendency for a more severe phenotype
         </strong>
         – Most studies have found that
         <em>
          TSC2
         </em>
         pathogenic variants tend to have a more severe neurologic phenotype and a higher risk of renal malignancy than
         <em>
          TSC1
         </em>
         pathogenic variants, but the relationship is not strict [
         <a href="#rid6">
          6,18,33-38
         </a>
         ]. As examples, a prospective study of 92 children with TSC who had genetic testing and evaluation of cognition, language, and motor development found that significant developmental delays at age 24 months were present in approximately three-quarters of those with a
         <em>
          TSC2
         </em>
         pathogenic variant and only one-quarter of patients with a
         <em>
          TSC1
         </em>
         pathogenic variant [
         <a href="#rid39">
          39
         </a>
         ]. Another report analyzed 120 pathogenic variants (22 involving
         <em>
          TSC1
         </em>
         and 98 involving
         <em>
          TSC2
         </em>
         ) in 150 patients with TSC and found that mental disability was significantly more frequent in patients with pathogenic variants involving
         <em>
          TSC2
         </em>
         compared with
         <em>
          TSC1
         </em>
         (67 versus 31 percent) [
         <a href="#rid18">
          18
         </a>
         ]. A similar difference was noted in a study of 252 patients with pathogenic variants in
         <em>
          TSC1
         </em>
         or
         <em>
          TSC2
         </em>
         [
         <a href="#rid6">
          6
         </a>
         ]. In addition, the same report found that hypomelanotic macules were more common in patients with
         <em>
          TSC2
         </em>
         pathogenic variants [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, some studies have found that patients with pathogenic variants involving
         <em>
          TSC1
         </em>
         and
         <em>
          TSC2
         </em>
         could not be distinguished on the basis of their clinical features [
         <a href="#rid17">
          17
         </a>
         ]. Further confounding this type of analysis is the fact that mosaicism for a TSC-associated "severe" pathogenic variant can result in a patient with mild features.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a later series, glioneuronal hamartomas with low fluid-attenuated inversion recovery (FLAIR) and T1-weighted signal intensity ("cyst-like") on brain magnetic resonance imaging (MRI) were found in all groups of patients but were significantly more frequent in patients with
         <em>
          TSC2
         </em>
         pathogenic variants than in those with
         <em>
          TSC1
         </em>
         pathogenic variants (relative risk [RR] 2.7, 95% CI 1.28-5.62) [
         <a href="#rid40">
          40
         </a>
         ]. Furthermore, these glioneuronal hamartomas were correlated with a history of infantile spasms, epilepsy, and severe refractory epilepsy. (See
         <a class="medical medical_review" href="/z/d/html/6175.html" rel="external">
          "Tuberous sclerosis complex: Clinical features", section on 'Seizures and epilepsy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Some
         </strong>
         <strong>
          <em>
           TSC2
          </em>
         </strong>
         <strong>
          variants have a mild phenotype
         </strong>
         – While
         <em>
          TSC2
         </em>
         pathogenic variants may generally have a more severe phenotype, mild forms of familial
         <em>
          TSC2
         </em>
         have been reported [
         <a href="#rid9">
          9,33,34,41
         </a>
         ]. In a study that identified 19 families with pathogenic variants at codon 905 of the
         <em>
          TSC2
         </em>
         gene, individuals with the
         <em>
          R905Q
         </em>
         pathogenic variant had unusually mild features of TSC, and many did not meet standard diagnostic criteria for TSC [
         <a href="#rid41">
          41
         </a>
         ]. By contrast, other missense changes at this same amino acid (R905W and R905G) were associated with more severe disease phenotype. These clinical findings also correlated with the results of in vitro functional analysis of the three pathogenic proteins.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2041782780">
         <span class="h3">
          <i>
           TSC1
          </i>
          variants
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          TSC1
         </em>
         pathogenic variants are underrepresented in patients presenting with de novo disease [
         <a href="#rid7">
          7,17,18,33,42
         </a>
         ]; individuals representing a single occurrence in a family (simplex cases) are more likely to have a
         <em>
          TSC2
         </em>
         than a
         <em>
          TSC1
         </em>
         pathogenic variant (ratio 3.4:1) [
         <a href="#rid7">
          7,9
         </a>
         ]. This difference may be due in part to ascertainment bias created by the possibility that
         <em>
          TSC1
         </em>
         pathogenic variants result in a less severe disease phenotype (particularly mental disability). This less severe phenotype, in the absence of a family history of TSC, may lead to delayed identification of de novo cases [
         <a href="#rid33">
          33,42
         </a>
         ]. (See
         <a class="local">
          'De novo versus familial TSC'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H657963390">
         <span class="h3">
          <i>
           TSC2
          </i>
          /
          <i>
           PKD1
          </i>
          contiguous gene syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         A small number of patients have deletions that inactivate both the
         <em>
          TSC2
         </em>
         gene and the polycystin 1 (
         <em>
          PKD1
         </em>
         ) gene that is located nearby, a disorder that is called the
         <em>
          TSC2/PKD1
         </em>
         contiguous gene syndrome. Affected patients have the clinical features of both TSC and polycystic kidney disease, and they typically present with early-onset renal cystic disease. (See
         <a class="medical medical_review" href="/z/d/html/1684.html" rel="external">
          "Renal manifestations of tuberous sclerosis complex", section on 'TSC2/PKD1 contiguous gene syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H952060905">
         <span class="h1">
          PATHOGENESIS
         </span>
        </p>
        <p class="headingAnchor" id="H1980111277">
         <span class="h2">
          Mechanism of tumor formation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several lines of evidence support the view that the TSC genes function as tumor suppressor genes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inactivating variants or complete loss of TSC genes are found in patients with TSC, and loss of heterozygosity at these gene loci characterize TSC-associated tumors (eg, hamartomas, angiofibromas, and lymphangioleiomyomas) [
         <a href="#rid30">
          30,43-47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In animal models, germline variants that disrupt either
         <em>
          TSC2
         </em>
         or
         <em>
          TSC1
         </em>
         predispose to hereditary clear cell renal cell carcinoma as well as multiple subependymal and extrarenal tumors such as subcortical hamartomas, similar to those encountered in patients with TSC [
         <a href="#rid48">
          48-50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reintroduction of wildtype, but not mutant, TSC protein suppresses tumor formation [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3906388812">
         <span class="h2">
          Role of mTOR
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most important advancement in our understanding of TSC is the delineation of the role of the hamartin-tuberin complex  (
         <a class="graphic graphic_figure graphicRef58634" href="/z/d/graphic/58634.html" rel="external">
          figure 1
         </a>
         ) through inhibition of cellular signaling mediated by the mechanistic target of rapamycin (mTOR) [
         <a href="#rid11">
          11,52-54
         </a>
         ]. The mTOR pathway is important for regulating cell growth and proliferation via protein translation (in response to nutrition), cell cycle progression, and response to hypoxia [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
         Pathogenic loss-of-function variants in
         <em>
          TSC1
         </em>
         , which encodes hamartin, or
         <em>
          TSC2
         </em>
         , which encodes tuberin, lead to destabilization of the hamartin-tuberin complex, the main negative modulator of the mTOR signaling pathway. This complex normally functions via GTPase-activating protein activity to cleave guanosine triphosphate (GTP) from Ras homolog enriched in brain (Rheb), a regulator of mTOR, and inhibit Rheb activity [
         <a href="#rid9">
          9,55,56
         </a>
         ]. mTOR interacts with raptor (regulatory protein associated with mTOR) and other components to form mTOR complex 1 (mTORC1). When activated via Rheb, mTORC1 leads to phosphorylation of downstream targets that regulate protein and lipid synthesis, cellular growth, mitochondrial proliferation, and autophagy.
        </p>
        <p>
         Thus, pathogenic
         <em>
          TSC1
         </em>
         or
         <em>
          TSC2
         </em>
         variants lead to inactivation of the tuberin-hamartin complex, loss of GTPase activity, an increase of GTP-activated Rheb, and hyperactivation of mTORC1 activity, thereby releasing an inhibitory influence on the cell cycle [
         <a href="#rid9">
          9,55,56
         </a>
         ]. The net result is that cells spend less time in G1, the resting phase of the cell cycle, and quiescent cells are induced to enter the cell cycle [
         <a href="#rid57">
          57,58
         </a>
         ]. Increased mTOR activity results in the formation of glioneuronal hamartomas in the brain and hamartomas in other organs [
         <a href="#rid56">
          56
         </a>
         ]. Increased mTOR activity during development may also impact the developing neural network, alter synaptic transmission, and shift the excitation/inhibition balance in favor of excitation; these changes could promote development of epilepsy and TSC-associated neuropsychiatric disorders (TAND) [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
         Recognition of the mTOR signaling pathway in the pathogenesis of TSC led to the development of mTOR inhibitors such as
         <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">
          everolimus
         </a>
         , the first agent for treatment of patients with TSC. (See
         <a class="medical medical_review" href="/z/d/html/16902.html" rel="external">
          "Tuberous sclerosis complex: Management and prognosis", section on 'Role of mTOR inhibitor therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4248590228">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          TSC disease genes
         </strong>
         – Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder caused by pathogenic variants in two separate genes,
         <em>
          TSC1
         </em>
         and
         <em>
          TSC2
         </em>
         . (See
         <a class="local">
          'TSC1 and TSC2 pathogenic variants'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic testing
         </strong>
         – With next-generation sequencing, targeted
         <em>
          TSC1
         </em>
         /
         <em>
          TSC2
         </em>
         gene panels can identify a causative pathogenic variant in &gt;90 percent of patients with TSC. (See
         <a class="local">
          'Molecular genetic testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inheritance
         </strong>
         – TSC is an autosomal dominant condition, but de novo germline pathogenic variants account for approximately 80 percent of TSC cases. These most often arise from a de novo pathogenic variant in the egg or sperm prior to fertilization. Other cases may be explained by parental somatic mosaicism, where a subset of somatic and/or germline cells carry the pathogenic variant, or by emergence of a de novo pathogenic variant after fertilization during one of the early cell divisions. (See
         <a class="local">
          'De novo versus familial TSC'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Penetrance and expressivity
         </strong>
         – The penetrance of
         <em>
          TSC1
         </em>
         and
         <em>
          TSC2
         </em>
         pathogenic variants is complete, but the disease is highly variable in its expression. (See
         <a class="local">
          'Penetrance and expressivity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genotype-phenotype correlations
         </strong>
         –
         <em>
          TSC2
         </em>
         pathogenic variants tend to have a more severe neurologic phenotype and a higher risk of renal malignancy than
         <em>
          TSC1
         </em>
         pathogenic variants, but the relationship is not strict, and the pathogenic variant result does not completely predict either the severity or nature of the disease complications. (See
         <a class="local">
          'Genotype-phenotype correlations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          mTOR pathway
         </strong>
         – Pathogenic
         <em>
          TSC1
         </em>
         or
         <em>
          TSC2
         </em>
         variants lead to inactivation of the tuberin-hamartin complex and hyperactivation of the mechanistic target of rapamycin (mTOR) signaling pathway. This leads to the various manifestations of TSC, including tumor formation in multiple organs and brain, epilepsy, and TSC-associated neuropsychiatric disorders (TAND). (See
         <a class="local">
          'Role of mTOR'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Curatolo P, Specchio N, Aronica E. Advances in the genetics and neuropathology of tuberous sclerosis complex: edging closer to targeted therapy. Lancet Neurol 2022; 21:843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Northrup H, Kwiatkowski DJ, Roach ES, et al. Evidence for genetic heterogeneity in tuberous sclerosis: one locus on chromosome 9 and at least one locus elsewhere. Am J Hum Genet 1992; 51:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sampson JR, Harris PC. The molecular genetics of tuberous sclerosis. Hum Mol Genet 1994; 3 Spec No:1477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Slegtenhorst M, de Hoogt R, Hermans C, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997; 277:805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993; 75:1305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Au KS, Williams AT, Roach ES, et al. Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet Med 2007; 9:88.
          </a>
         </li>
         <li class="breakAll">
          Northrup H, Koenig MK, Pearson DA, Au KS. Tuberous sclerosis complex. In: GeneReviews [Internet], Adam MP, Mirzaa GM, Pagon RA, et al. (Eds), University of Washington, Seattle. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1220/ (Accessed on September 06, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tyburczy ME, Dies KA, Glass J, et al. Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing. PLoS Genet 2015; 11:e1005637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peron A, Au KS, Northrup H. Genetics, genomics, and genotype-phenotype correlations of TSC: Insights for clinical practice. Am J Med Genet C Semin Med Genet 2018; 178:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamb RF, Roy C, Diefenbach TJ, et al. The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat Cell Biol 2000; 2:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tee AR, Fingar DC, Manning BD, et al. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A 2002; 99:13571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Slegtenhorst M, Nellist M, Nagelkerken B, et al. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum Mol Genet 1998; 7:1053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwiatkowska J, Jozwiak S, Hall F, et al. Comprehensive mutational analysis of the TSC1 gene: observations on frequency of mutation, associated features, and nonpenetrance. Ann Hum Genet 1998; 62:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wienecke R, König A, DeClue JE. Identification of tuberin, the tuberous sclerosis-2 product. Tuberin possesses specific Rap1GAP activity. J Biol Chem 1995; 270:16409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rennebeck G, Kleymenova EV, Anderson R, et al. Loss of function of the tuberous sclerosis 2 tumor suppressor gene results in embryonic lethality characterized by disrupted neuroepithelial growth and development. Proc Natl Acad Sci U S A 1998; 95:15629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pajak L, Jin F, Xiao GH, et al. Sustained cardiomyocyte DNA synthesis in whole embryo cultures lacking the TSC2 gene product. Am J Physiol 1997; 273:H1619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niida Y, Lawrence-Smith N, Banwell A, et al. Analysis of both TSC1 and TSC2 for germline mutations in 126 unrelated patients with tuberous sclerosis. Hum Mutat 1999; 14:412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones AC, Shyamsundar MM, Thomas MW, et al. Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet 1999; 64:1305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Au KS, Rodriguez JA, Finch JL, et al. Germ-line mutational analysis of the TSC2 gene in 90 tuberous-sclerosis patients. Am J Hum Genet 1998; 62:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nellist M, Verhaaf B, Goedbloed MA, et al. TSC2 missense mutations inhibit tuberin phosphorylation and prevent formation of the tuberin-hamartin complex. Hum Mol Genet 2001; 10:2889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hodges AK, Li S, Maynard J, et al. Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin. Hum Mol Genet 2001; 10:2899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feliciano DM. The Neurodevelopmental Pathogenesis of Tuberous Sclerosis Complex (TSC). Front Neuroanat 2020; 14:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Northrup H, Aronow ME, Bebin EM, et al. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr Neurol 2021; 123:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nellist M, Brouwer RW, Kockx CE, et al. Targeted Next Generation Sequencing reveals previously unidentified TSC1 and TSC2 mutations. BMC Med Genet 2015; 16:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rose VM, Au KS, Pollom G, et al. Germ-line mosaicism in tuberous sclerosis: how common? Am J Hum Genet 1999; 64:986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwiatkowska J, Wigowska-Sowinska J, Napierala D, et al. Mosaicism in tuberous sclerosis as a potential cause of the failure of molecular diagnosis. N Engl J Med 1999; 340:703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verhoef S, Bakker L, Tempelaars AM, et al. High rate of mosaicism in tuberous sclerosis complex. Am J Hum Genet 1999; 64:1632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Northrup H, Wheless JW, Bertin TK, Lewis RA. Variability of expression in tuberous sclerosis. J Med Genet 1993; 30:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smalley SL, Burger F, Smith M. Phenotypic variation of tuberous sclerosis in a single extended kindred. J Med Genet 1994; 31:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Au KS, Hebert AA, Roach ES, Northrup H. Complete inactivation of the TSC2 gene leads to formation of hamartomas. Am J Hum Genet 1999; 65:1790.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kobayashi T, Urakami S, Hirayama Y, et al. Intragenic Tsc2 somatic mutations as Knudson's second hit in spontaneous and chemically induced renal carcinomas in the Eker rat model. Jpn J Cancer Res 1997; 88:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knudson AG Jr, Hethcote HW, Brown BW. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc Natl Acad Sci U S A 1975; 72:5116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones AC, Daniells CE, Snell RG, et al. Molecular genetic and phenotypic analysis reveals differences between TSC1 and TSC2 associated familial and sporadic tuberous sclerosis. Hum Mol Genet 1997; 6:2155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dabora SL, Jozwiak S, Franz DN, et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 2001; 68:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jansen FE, Braams O, Vincken KL, et al. Overlapping neurologic and cognitive phenotypes in patients with TSC1 or TSC2 mutations. Neurology 2008; 70:908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang P, Cornejo KM, Sadow PM, et al. Renal cell carcinoma in tuberous sclerosis complex. Am J Surg Pathol 2014; 38:895.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kothare SV, Singh K, Chalifoux JR, et al. Severity of manifestations in tuberous sclerosis complex in relation to genotype. Epilepsia 2014; 55:1025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Numis AL, Major P, Montenegro MA, et al. Identification of risk factors for autism spectrum disorders in tuberous sclerosis complex. Neurology 2011; 76:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farach LS, Pearson DA, Woodhouse JP, et al. Tuberous Sclerosis Complex Genotypes and Developmental Phenotype. Pediatr Neurol 2019; 96:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chu-Shore CJ, Major P, Montenegro M, Thiele E. Cyst-like tubers are associated with TSC2 and epilepsy in tuberous sclerosis complex. Neurology 2009; 72:1165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jansen AC, Sancak O, D'Agostino MD, et al. Unusually mild tuberous sclerosis phenotype is associated with TSC2 R905Q mutation. Ann Neurol 2006; 60:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langkau N, Martin N, Brandt R, et al. TSC1 and TSC2 mutations in tuberous sclerosis, the associated phenotypes and a model to explain observed TSC1/ TSC2 frequency ratios. Eur J Pediatr 2002; 161:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green AJ, Smith M, Yates JR. Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients. Nat Genet 1994; 6:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henske EP, Neumann HP, Scheithauer BW, et al. Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas. Genes Chromosomes Cancer 1995; 13:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henske EP, Scheithauer BW, Short MP, et al. Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet 1996; 59:400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carbonara C, Longa L, Grosso E, et al. 9q34 loss of heterozygosity in a tuberous sclerosis astrocytoma suggests a growth suppressor-like activity also for the TSC1 gene. Hum Mol Genet 1994; 3:1829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carbonara C, Longa L, Grosso E, et al. Apparent preferential loss of heterozygosity at TSC2 over TSC1 chromosomal region in tuberous sclerosis hamartomas. Genes Chromosomes Cancer 1996; 15:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeung RS, Xiao GH, Jin F, et al. Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene. Proc Natl Acad Sci U S A 1994; 91:11413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kobayashi T, Minowa O, Sugitani Y, et al. A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice. Proc Natl Acad Sci U S A 2001; 98:8762.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Onda H, Lueck A, Marks PW, et al. Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J Clin Invest 1999; 104:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jin F, Wienecke R, Xiao GH, et al. Suppression of tumorigenicity by the wild-type tuberous sclerosis 2 (Tsc2) gene and its C-terminal region. Proc Natl Acad Sci U S A 1996; 93:9154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 2008; 372:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwiatkowski DJ, Manning BD. Molecular basis of giant cells in tuberous sclerosis complex. N Engl J Med 2014; 371:778.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Child ND, Benarroch EE. mTOR: its role in the nervous system and involvement in neurologic disease. Neurology 2014; 83:1562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell 2017; 168:960.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bassetti D, Luhmann HJ, Kirischuk S. Effects of Mutations in TSC Genes on Neurodevelopment and Synaptic Transmission. Int J Mol Sci 2021; 22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soucek T, Yeung RS, Hengstschläger M. Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. Proc Natl Acad Sci U S A 1998; 95:15653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soucek T, Pusch O, Wienecke R, et al. Role of the tuberous sclerosis gene-2 product in cell cycle control. Loss of the tuberous sclerosis gene-2 induces quiescent cells to enter S phase. J Biol Chem 1997; 272:29301.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 142618 Version 1.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35963265" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Advances in the genetics and neuropathology of tuberous sclerosis complex: edging closer to targeted therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1415216" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Evidence for genetic heterogeneity in tuberous sclerosis: one locus on chromosome 9 and at least one locus elsewhere.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7849741" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The molecular genetics of tuberous sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9242607" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8269512" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Identification and characterization of the tuberous sclerosis gene on chromosome 16.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17304050" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17304050" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26540169" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30255984" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Genetics, genomics, and genotype-phenotype correlations of TSC: Insights for clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10806479" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12271141" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9580671" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9924605" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Comprehensive mutational analysis of the TSC1 gene: observations on frequency of mutation, associated features, and nonpenetrance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7608212" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Identification of tuberin, the tuberous sclerosis-2 product. Tuberin possesses specific Rap1GAP activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9861021" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Loss of function of the tuberous sclerosis 2 tumor suppressor gene results in embryonic lethality characterized by disrupted neuroepithelial growth and development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9321857" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Sustained cardiomyocyte DNA synthesis in whole embryo cultures lacking the TSC2 gene product.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10533067" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Analysis of both TSC1 and TSC2 for germline mutations in 126 unrelated patients with tuberous sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10205261" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9463313" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Germ-line mutational analysis of the TSC2 gene in 90 tuberous-sclerosis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11741832" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : TSC2 missense mutations inhibit tuberin phosphorylation and prevent formation of the tuberin-hamartin complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11741833" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32765227" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The Neurodevelopmental Pathogenesis of Tuberous Sclerosis Complex (TSC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34399110" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25927202" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Targeted Next Generation Sequencing reveals previously unidentified TSC1 and TSC2 mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10090883" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Germ-line mosaicism in tuberous sclerosis: how common?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10053179" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Mosaicism in tuberous sclerosis as a potential cause of the failure of molecular diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10330349" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : High rate of mosaicism in tuberous sclerosis complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8423606" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Variability of expression in tuberous sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7837252" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Phenotypic variation of tuberous sclerosis in a single extended kindred.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10577937" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Complete inactivation of the TSC2 gene leads to formation of hamartomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9140109" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Intragenic Tsc2 somatic mutations as Knudson's second hit in spontaneous and chemically induced renal carcinomas in the Eker rat model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1061095" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9328481" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Molecular genetic and phenotypic analysis reveals differences between TSC1 and TSC2 associated familial and sporadic tuberous sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11112665" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18032745" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Overlapping neurologic and cognitive phenotypes in patients with TSC1 or TSC2 mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24832166" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Renal cell carcinoma in tuberous sclerosis complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24917535" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Severity of manifestations in tuberous sclerosis complex in relation to genotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21403110" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Identification of risk factors for autism spectrum disorders in tuberous sclerosis complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31005478" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Tuberous Sclerosis Complex Genotypes and Developmental Phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19332694" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Cyst-like tubers are associated with TSC2 and epilepsy in tuberous sclerosis complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17120248" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Unusually mild tuberous sclerosis phenotype is associated with TSC2 R905Q mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12111193" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : TSC1 and TSC2 mutations in tuberous sclerosis, the associated phenotypes and a model to explain observed TSC1/ TSC2 frequency ratios.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8162074" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7547639" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8755927" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7849708" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : 9q34 loss of heterozygosity in a tuberous sclerosis astrocytoma suggests a growth suppressor-like activity also for the TSC1 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8824721" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Apparent preferential loss of heterozygosity at TSC2 over TSC1 chromosomal region in tuberous sclerosis hamartomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7972075" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11438694" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10491404" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8799170" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Suppression of tumorigenicity by the wild-type tuberous sclerosis 2 (Tsc2) gene and its C-terminal region.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18722871" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Tuberous sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25140966" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Molecular basis of giant cells in tuberous sclerosis complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25253752" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : mTOR: its role in the nervous system and involvement in neurologic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28283069" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : mTOR Signaling in Growth, Metabolism, and Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34298906" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Effects of Mutations in TSC Genes on Neurodevelopment and Synaptic Transmission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9861025" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9361010" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Role of the tuberous sclerosis gene-2 product in cell cycle control. Loss of the tuberous sclerosis gene-2 induces quiescent cells to enter S phase.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
